NephroGenex Inc

NephroGenex — IPO Roadshow (January 2014)

33 slides from NephroGenex's IPO roadshow presentation, Jan 21, 2014

  1. Slide 1: Company Overview January 2014

    Company Overview January 2014 April 2012

  2. Slide 2: Forward-looking statements

    This presentation includes statements that are, or may be deemed, ‘‘forward - looking statements.’’ In some cases, these forward - l ooking statements can be identified by the use of forward - looking terminology, including the terms “believes,” “estimates,” “anticipate s,” “expects,” “plans,” “inte

  3. Slide 3: Free Writing Prospectus Statement

    Free Writing Prospectus Statement This presentation highlights basic information about us and the offering. Because it is a summary, it does not contain all of th e information that you should consider before investing. We have filed a registration statement (including a preliminary prospectus) with

  4. Slide 4: Offering Summary

    Offering Summary Issuer NephroGenex, Inc. Listing / Ticker NASDAQ Capital Market / NRX Shares Offered 3,100,000 Shares (100% Primary) Overallotment Option 15% (100% Primary) Price Range $12 - $14 per Share Expected Pricing Range Week of February 3, 2014 Use of Proceeds Clinical development of Oral P

  5. Slide 5: Key Management

    Key Management Members 4 Management Past Experie nce Pierre Legault , CEO Eckerd , President OSI Pharmaceuticals , CFO Rite Aid , CAO Sanofi - Aventis , President Worldwide Dermatology Prosidion Ltd , CEO Board Member , Forest Labs & Regado Biosciences Wesley Fox, President & CSO BioStratum , Co - F

  6. Slide 6: NephroGenex Investors and Board of Directors

    NephroGenex Investors Board of Directors Member Position, Affiliation Pierre Legault Director , NephroGenex J.Wesley Fox Director , NephroGenex Robert Seltzer Director , Care Capital Eugene Steiner, M.D. Director , BioStratum Martin Vogelbaum Director , Rho Ventures Current Investors Chairman of the

  7. Slide 7: Corporate Overview

    Corporate Overview 6 Late - stage company focused on developing pathogenic oxidative chemistry inhibitors to treat kidney disease ▪ Oral Pyridorin – slows down progression of diabetic nephropathy (DN) ▪ IV Pyridorin – treatment for acute kidney injury (AKI) exacerbated by oxidative chemistries Oral

  8. Slide 8: The NephroGenex Pipeline

    The NephroGenex Pipeline Clinical Program / Indication Preclinical Phase I Phase II Phase III Worldwide Commercial Rights ORAL PYRIDORIN ® Diabetic Nephropathy IV PYRIDORIN ® Acute Kidney Injury Clinical Program 7

  9. Slide 9: Oral Pyridorin for Diabetic Nephropathy Overview

    Oral Pyridorin for Diabetic Nephropathy Overview 8

  10. Slide 10: Diabetic Nephropathy Overview

    Diabetic nephropathy (DN) ▪ ‘ Microalbuminuria ’ ‘ Macroalbuminuria ’ Onset of renal insufficiency End stage renal disease (ESRD) and Dialysis Diabetic nephropathy is a significant healthcare financial burden Current approved therapies are marginally effective ▪ Only ACEIs and ARBs are approved for

  11. Slide 11: Oral Pyridorin Market Potential

    Oral Pyridorin Market Potential 10 DN patients eventually progress to dialysis or death 19 M diagnosed diabetics in the US, of which 33% are diagnosed for nephropathy (6.3 M) ▪ 2.8 M patients microalbuminuria referred to as overt nephropathy ▪ 3.5 M with microalbuminurea (early stage DN) ▪ An additi

  12. Slide 12: Pyridorin targets oxidative chemistries in DN

    Hyperglycemia increases pathogenic oxidative chemistries* ▪ Elevated levels of oxidative chemistries promote the development and progression of DN* Pyridorin targets oxidative chemistries, a key underlying cause of DN ▪ DN is the leading cause of dialysis and chronic kidney failure Pyridorin is an e

  13. Slide 13: Pyridorin Mechanism of Action

    Pyridorin Mechanism of Action O 2 /M n+ Protein Protein Protein Schiff base O 2 /M n+ O 2 /M n+ Reactive carbonyl species MGO & 3 - DG and ROS O 2 /M n+ Protein Protein Amadori A.G.E. Protein A.G.E. Glucose Toxic carbonyl compounds Advanced glycation end - products ROS - Reactive oxygen species Adva

  14. Slide 14: Pyridorin Phase 2a Program PYR-206

    Multi - center, randomized, double - blind, placebo - controlled trial ▪ Number of centers: 46 ▪ Location of centers: U.S. ▪ Dose: 50mg BID x 24 weeks ▪ Study objectives: assess safety, tolerability and biological activity Diabetic patients with DN due to type 1 or type 2 diabetes ▪ N = 128 (65 trea

  15. Slide 15: Clinical Results PYR-206

    Mild to Moderate Diabetic Nephropathy – Dose 50 mg BID Patient Population Number of Subjects PYR, Placebo Baseline SCr PYR Placebo SCr Change from Baseline PYR Placebo Pyridorin Treatment Effect P value All Patients 65, 63 1.27 ± 0.34 1.33 ± 0.38 0.12 ± 0.40 0.16 ± 0.28 27% 0.2426 Type 2 Diabetes 40

  16. Slide 16: Pyridorin Phase 2a Program PYR-205/207

    Two multi - center, randomized, double - blind, placebo - controlled trials ▪ Number of centers: 20 ▪ Location of centers: U.S., Belgium, United Kingdom, Canada, South Africa ▪ Dose: 50mg BID x 2 weeks; 100mg BID x 2 weeks; 250mg BID x 20 weeks ▪ Study objectives: assess safety, tolerability and bio

  17. Slide 17: Clinical Results PYR-205/207

    Moderate to Advanced Diabetic Nephropathy – Dose 250 mg bid Patient Population Number of Subjects PYR, Placebo Baseline SCr PYR Placebo SCr Change from Baseline PYR Placebo Pyridorin Treatment Effect P value All Patients 57 , 27 1.75 ± 0.64 1.96 ± 0.86 0.11 ± 0.26 0.34 ± 0.92 68% 0.0322* Type 2 Diab

  18. Slide 18: Pyridorin Phase 2b Program PYR-210

    Multi - center, randomized, double - blind, placebo - controlled ▪ Number of centers: 61 ▪ Location of centers: U.S., Australia, Israel ▪ Doses:150mg BID x 12 months; 300mg BID x 12 months ▪ Endpoint: year - one SCr change Diabetic patients with DN due to type 2 diabetes ▪ N=307 (105 treated @ 300 m

  19. Slide 19: Clinical Results PYR-210

    Clinical Results PYR - 210 Patient Population Dose Number of Subjects PYR, Placebo Baseline SCr PYR Placebo SCr Change from Baseline PYR Placebo Pyridorin Treatment Effect P value Patients NOT on SOC at screening 3 Pre - specified analysis 300 mg 36, 34 2.32 ± 0.50 2.34 ± 0.67 0.62 ± 0.75 0.31 ± 0.6

  20. Slide 20: Oral Pyridorin Phase 3 development

    Oral Pyridorin Phase 3 development 19

  21. Slide 21: Pyridorin Phase 3 Protocol

    Objective ▪ Evaluate efficacy of Pyridorin at a 300mg twice daily dose compared to placebo to reduce the rate of renal disease progression due to type 2 diabetes mellitus Patient Population ▪ Type 2 diabetic nephropathy patients − Patients with overt nephropathy exhibiting a PCR >1200 mg/g − Baselin

  22. Slide 22: Pyridorin Phase 3 Protocol: trial design

    Overall trial design ▪ Two identical,double - blind Phase 3 studies of 600 patients each ▪ Dose 300 mg bid ▪ Patient mean follow - up of 30 months ▪ DN centers world - wide Powering ▪ 247 events ▪ 90% powering to detect a 28% treatment effect (>50% treatment effect observed in Phase 2b study in rele

  23. Slide 23: Timeline for PYR-311

    SPA & endpoint approval by FDA 2014 2015 2017 2013 $20 M $10 M Total $30 M Timeline for PYR - 311 PYR - 311 600 Patients PYR - 311 Initiation Recruitment completed Interim Analysis Trial Completion 2016 2018 First patient treated 22

  24. Slide 24: IP & Product Exclusivity

    United States ▪ Patient population IP protection until June 2024/September 2028 with patent extension IP & Product Exclusivity Europe & Canada ▪ Dosage and patient population IP protection through June 2024 ▪ New chemical entity status (NCE) provides data exclusivity protection for 8 years in Canada

  25. Slide 25: IV Pyridorin Overview

    e@ NephroGenex povatve Therapies for Kidney Disease IV Pyridorin Overview

  26. Slide 26: IV Pyridorin for acute kidney injury

    ▪ Pyridorin targets specific pathogenic oxidative chemistries that emerge in diabetes ▪ These pathogenic oxidative chemistries also emerge in acute kidney injury caused by: − Reperfusion injury in CV surgery − Contrast media in angiography − Severe AKI may result in acute renal failure (ARF) IV Pyri

  27. Slide 27: NephroGenex Corporate Overview

    NephroGenex Corporate Overview 26

  28. Slide 28: Financial Snapshot

    Financial Snapshot 27 IPO Target Amount IPO Expected Gross Proceeds $40.3 M Company Shares Existing Shares 5.7 M New Shares 3.1 M Operating Expenses (FY 2014) Amount Research & Development $9 M General & Administrative (including IPO) $6 M Total Burn $15 M Financial Snapshot 27 IPO Target Amount IPO

  29. Slide 29: Projected Corporate Milestones

    Projected Corporate Milestones 1H 2014 ▪ NephroGenex Initial Public Offering ▪ PYR - 311 first patient enrolled 2H 2014 ▪ TQT cardiac safety study completed ▪ New SCr increase endpoint accepted by EMA 1H 2015 ▪ IV PYR for AKI preclinical results completed ▪ IND for IV PYR AKI filed 2H 2015 ▪ IV PYR

  30. Slide 30: Corporate Summary

    Corporate Summary Experienced management team focused on clinical success Diabetic nephropathy represents a large and growing unmet need Oral Pyridorin could potentially treat as many as 10 M patients, more than half of the diabetic population in the US ▪ No alternative treatments for DN ▪ Pyridorin

  31. Slide 31: Appendix

    e@ NephroGenex Therapies for Kidney Disease Appendix

  32. Slide 32: Previous DN Phase 3 trial failures

    31 Pimagedine , Sulonex , Avosentan and Bardoxolone have all failed in Phase 3 trials for DN All 4 drugs had significant differences between their Phase 2 and Phase 3 studies: ▪ Phase 2 studies conducted in narrow, less diseased patient populations ▪ Phase 2 used surrogate endpoints (not based on SC

  33. Slide 33: New DN Phase 3 Endpoint

    ▪ FDA and National Kidney Foundation held a Workshop in 4Q 2012 to study ‘ GFR Decline as an Endpoint for Clinical Trials in Chronic Kidney Disease ’ ▪ Workshop concluded that levels of SCr increase substantially lower than doubling can serve as workable endpoints in clinical trials ▪ Findings valid

NephroGenex — IPO Roadshow (January 2014) on 6ix